Beam Therapeutics BEAM and Intellia Therapeutics NTLA are clinical-stage companies developing investigational gene therapies.

Shares of Beam Therapeutics Inc. BEAM have rallied 27.3% in the past three months compared with the industry’s increase of 9.8%. Beam’s pipeline of gene editing therapies is based on its proprietary ...

Beam Therapeutics Inc. is a Strong Buy with promising trial results, a solid cash runway, and key data updates ahead. Click ...

As of Wednesday, December 03, Beam Therapeutics Inc.’s BEAM share price has surged by 6.50%, which has investors questioning ...

A Beam Therapeutics gene-editing therapy designed to fix a mutation at the root of a rare liver protein deficiency now has early signs of efficacy along with safety data that ease some concerns about ...

Beam Therapeutics' pipeline, including BEAM-101, BEAM-201, and BEAM-302, shows promise but remains in early stages with no clinical trial data yet available. Despite a strong cash position, Beam's ...

Precision gene-editing company Beam Therapeutics (NASDAQ: BEAM) had a Tuesday to forget on the stock market. Following the release that morning of its latest set of quarterly results, the shares raced ...

We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Beam Therapeutics Inc. (NASDAQ:BEAM) stands ...

Pre-revenue biotechs like Beam Therapeutics bring plenty of risk. The good news is that it has plenty of money and some help from Pfizer, too. But it's targeting crowded markets, and it already has a ...

Beam, which is still in the clinical stage, earned slightly under $7.5 million in its first quarter of the year on license and collaboration revenue. That was largely flat year over year. With an ...